{
    "organizations": [],
    "uuid": "c73549223fbe99a77d418c02f61631b81109f06b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-altimmune-announces-positive-data/brief-altimmune-announces-positive-data-from-its-phase-2a-study-of-nasovax-intranasal-influenza-vaccine-idUSASC09TRI",
    "ord_in_thread": 0,
    "title": "BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 08 PM / Updated 23 minutes ago BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine Reuters Staff 1 Min Read March 27 (Reuters) - Altimmune Inc: * ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION * ALTIMMUNE INC - HEPTCELL VACCINE WAS WELL TOLERATED BUT T-CELL IMMUNOGENICITY RESULTS WERE INCONCLUSIVE * ALTIMMUNE - RESULTS FROM NASOVAX INTRANASAL FLU VACCINE PHASE 2A STUDY IN 60 HEALTHY INDIVIDUALS SHOWED 100% SEROPROTECTION IN MID- & HIGH-DOSE GROUPS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-27T15:07:00.000+03:00",
    "crawled": "2018-03-27T15:36:17.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "positive",
        "data",
        "phase",
        "2a",
        "study",
        "nasovax",
        "intranasal",
        "influenza",
        "vaccine",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "altimmune",
        "inc",
        "altimmune",
        "announces",
        "positive",
        "data",
        "phase",
        "2a",
        "study",
        "nasovax",
        "intranasal",
        "influenza",
        "vaccine",
        "provides",
        "update",
        "phase",
        "1b",
        "study",
        "heptcell",
        "targeted",
        "immunotherapy",
        "chronic",
        "hepatitis",
        "b",
        "infection",
        "altimmune",
        "inc",
        "heptcell",
        "vaccine",
        "well",
        "tolerated",
        "immunogenicity",
        "result",
        "inconclusive",
        "altimmune",
        "result",
        "nasovax",
        "intranasal",
        "flu",
        "vaccine",
        "phase",
        "2a",
        "study",
        "healthy",
        "individual",
        "showed",
        "seroprotection",
        "group",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}